Individual Dose-escalated Bi-daily Subcutaneously (sc) Ghrelin in Cancer Cachexia: a Phase I/II Study

NCT00933361 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Advanced Cancer
Cachexia

Interventions

DRUG: ghrelin

Sponsor

Cantonal Hospital of St. Gallen

Collaborators

[object Object]